Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo

Ruzieh, Mohammed; Moroi, Morgan K.; Aboujamous, Nader M.; Ghahramani, Mehrdad; Naccarelli, Gerald V.; Mandrola, John; Foy, Andrew

doi:10.1016/j.amjcard.2019.09.008

Cited by 34 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ruzieh et al reported that the likelihood of experiencing an amiodarone-related adverse event was greater than with placebo. (relative risk about 4.44 versus placebo) ( Ruzieh et al, 2019 ). In the following sections (6.2 to 6.4), we summarize the effect of amiodarone on thyroid function in detail.…”

Section: Drug-induced Thyroid Dysfunctionmentioning

confidence: 99%

Thyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

Thyroid hormones (THs) are synthesized in the thyroid gland, and they circulate in the blood to regulate cells, tissues, and organs in the body. In particular, they exert several effects on the cardiovascular system. It is well known that THs raise the heart rate and cardiac contractility, improve the systolic and diastolic function of the heart, and decrease systemic vascular resistance. In the past 30 years, some researchers have studied the molecular pathways that mediate the role of TH in the cardiovascular system, to better understand its mechanisms of action. Two types of mechanisms, which are genomic and non-genomic pathways, underlie the effects of THs on cardiomyocytes. In this review, we summarize the current knowledge of the action of THs in the cardiac function, the clinical manifestation and parameters of their hemodynamics, and treatment principles for patients with hyperthyroid- or hypothyroid-associated heart disease. We also describe the cardiovascular drugs that induce thyroid dysfunction and explain the mechanism underlying the thyroid toxicity of amiodarone, which is considered the most effective antiarrhythmic agent. Finally, we discuss the recent reports on the involvement of thyroid hormones in the regulation of myocardial regeneration and metabolism in the adult heart.

show abstract

Section: Drug-induced Thyroid Dysfunctionmentioning

confidence: 99%

Thyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The prohibition of flecainide in patients with ischaemic heart disease is based on the results of the CAST [5] which demonstrated that flecainide is associated with increased mortality in patients with prior MI and LV dysfunction. This study severely influenced and restricted the current use of flecainide in clinical practice for decades, causing a fall in employment of class IC AADs in favor of class III AADs [7,8] and exposing patients to the numerous adverse reactions and toxicities of these drugs [9]. Specifically, in the CAST trial, 1498 patients with prior MI within 6 days to 2 years before enrollment and with LVEF ≤ 0.55, at least 6 PVCs per hour and no episodes of VT ≥ 15 beats or with rate above 120 bpm were randomized either to flecainide or encainide or placebo treatment.…”

Section: Ischaemic Heart Diseasementioning

confidence: 99%

“…Thus, the CAST significantly affected and restricted the current use of flecainide in clinical practice causing a fall in employment of class IC AADs in favor of class III AADs [7,8] and exposing patients to the numerous adverse reactions and toxicities of these drugs, in the absence of a robust evidence [9,10].…”

Section: Introductionmentioning

confidence: 99%

Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives

Lavalle

Trivigno

Vetta

et al. 2021

JCM

View full text Add to dashboard Cite

Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.

show abstract

“…Articles were identified using key search terms: amiodarone, adverse events, side effects, placebo, atrial fibrillation, atrial flutter, ventricular tachycardia, arrhythmias, liver, skin, thyroid, eye, and lung. References of all identified studies were also hand-searched for inclusion to identify additional relevant studies [1].…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

Dataset for amiodarone adverse events compared to placebo using data from randomized controlled trials

et al. 2020

Self Cite

View full text Add to dashboard Cite

The dataset presented here provides a detailed description of the adverse events of amiodarone versus placebo using data from 43 randomized controlled trials. Two authors (M.M., M.R.) independently extracted the data. The dataset also includes baseline patient characteristics, amiodarone loading and maintenance doses, as well as forest plots describing the relative risk (RR) of developing an adverse event related to the pulmonary, thyroid, hepatic, cardiac, skin, gastrointestinal, neurological, and ocular systems. The Mantel-Haenszel random effects model was used to determine the relative risk of adverse events of amiodarone compared to placebo. This dataset is complementary to our article “Meta-analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo”, which was published in the American Journal of Cardiology [1]. The data can be used to assess certain adverse events and their relation to amiodarone loading and/or maintenance dose.

show abstract

Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo

Cited by 34 publications

References 6 publications

Thyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside

Thyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside

Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives

Dataset for amiodarone adverse events compared to placebo using data from randomized controlled trials

Contact Info

Product

Resources

About